Skip to Content
COVID-19 Resources
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 02/21/20

Prostate SPOREs

Prostate cancer (PrCa) is the most commonly diagnosed cancer in men with the highest incidence in black men. In 2019, there was an estimated 174,650* new cases of PrCa and 31,620 deaths from this disease reported in the United States. The percent of patients surviving for 5 years is 98%. The current PrCa SPOREs are highly collaborative translational research teams, sharing resources and conducting inter-institutional clinical studies for the prevention, monitoring, and treatment of PrCa. They play a central role in advancing translational cancer research with academia, industry, other government agencies, and the international research community. Translational research projects within the prostate SPORES explore the comprehensive landscape of PrCa research including impact of genetics involved in active surveillance, the molecular evolution of resistance to androgen deprivation therapies and the development of neuroendocrine prostate cancer, cellular mechanisms involved in metastatic PrCa, exploring novel inhibitors of the androgen receptor pathway, targeting repair of DNA damage, blood and urine biomarkers for risk stratification, and many more pioneering projects; all aimed at bringing targeted therapies to clinical trials.